347 related articles for article (PubMed ID: 17928873)
1. Generation of a high-titer packaging cell line for the production of retroviral vectors in suspension and serum-free media.
Ghani K; Cottin S; Kamen A; Caruso M
Gene Ther; 2007 Dec; 14(24):1705-11. PubMed ID: 17928873
[TBL] [Abstract][Full Text] [Related]
2. Retroviral vector production using suspension-adapted 293GPG cells in a 3L acoustic filter-based perfusion bioreactor.
Ghani K; Garnier A; Coelho H; Transfiguracion J; Trudel P; Kamen A
Biotechnol Bioeng; 2006 Nov; 95(4):653-60. PubMed ID: 16947907
[TBL] [Abstract][Full Text] [Related]
3. A novel human suspension culture packaging cell line for production of high-titre retroviral vectors.
Chan LM; Coutelle C; Themis M
Gene Ther; 2001 May; 8(9):697-703. PubMed ID: 11406764
[TBL] [Abstract][Full Text] [Related]
4. Suspension packaging cell lines for the simplified generation of T-cell receptor encoding retrovirus vector particles.
Reuss S; Biese P; Cosset FL; Takeuchi Y; Uckert W
Gene Ther; 2007 Apr; 14(7):595-603. PubMed ID: 17235289
[TBL] [Abstract][Full Text] [Related]
5. Effects of culture parameters on the production of retroviral vectors by a human packaging cell line.
McTaggart S; Al-Rubeai M
Biotechnol Prog; 2000; 16(5):859-65. PubMed ID: 11027182
[TBL] [Abstract][Full Text] [Related]
6. A retroviral packaging cell line for pseudotype vectors based on glioma-infiltrating progenitor cells.
Fischer YH; Miletic H; Giroglou T; Litwak S; Stenzel W; Neumann H; von Laer D
J Gene Med; 2007 May; 9(5):335-44. PubMed ID: 17474071
[TBL] [Abstract][Full Text] [Related]
7. Production of retroviral vectors for gene therapy with the human packaging cell line FLYRD18.
Gerin PA; Searle PF; Al-Rubeai M
Biotechnol Prog; 1999; 15(5):941-8. PubMed ID: 10514266
[TBL] [Abstract][Full Text] [Related]
8. Development and characterization of a cell line for large-scale, serum-free production of recombinant adeno-associated viral vectors.
Farson D; Harding TC; Tao L; Liu J; Powell S; Vimal V; Yendluri S; Koprivnikar K; Ho K; Twitty C; Husak P; Lin A; Snyder RO; Donahue BA
J Gene Med; 2004 Dec; 6(12):1369-81. PubMed ID: 15538729
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of retroviral production from packaging cell lines expressing the human immunodeficiency type 1 VPU gene.
Kobinger GP; Mouland AJ; Lalonde JP; Forget J; Cohen EA
Gene Ther; 1997 Aug; 4(8):868-74. PubMed ID: 9338017
[TBL] [Abstract][Full Text] [Related]
10. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector.
Ni Y; Sun S; Oparaocha I; Humeau L; Davis B; Cohen R; Binder G; Chang YN; Slepushkin V; Dropulic B
J Gene Med; 2005 Jun; 7(6):818-34. PubMed ID: 15693055
[TBL] [Abstract][Full Text] [Related]
11. Development of a suspension packaging cell line for production of high titre, serum-resistant murine leukemia virus vectors.
Pizzato M; Merten OW; Blair ED; Takeuchi Y
Gene Ther; 2001 May; 8(10):737-45. PubMed ID: 11420637
[TBL] [Abstract][Full Text] [Related]
12. Construction of a retroviral vector production system with the minimum possibility of a homologous recombination.
Yu SS; Han E; Hong Y; Lee JT; Kim S; Kim S
Gene Ther; 2003 Apr; 10(8):706-11. PubMed ID: 12692599
[TBL] [Abstract][Full Text] [Related]
13. Comparison of different bioreactor systems for the production of high titer retroviral vectors.
Merten OW; Cruz PE; Rochette C; Geny-Fiamma C; Bouquet C; Gonçalves D; Danos O; Carrondo MJ
Biotechnol Prog; 2001; 17(2):326-35. PubMed ID: 11312711
[TBL] [Abstract][Full Text] [Related]
14. Construction and use of a safe and efficient amphotropic packaging cell line.
Markowitz D; Goff S; Bank A
Virology; 1988 Dec; 167(2):400-6. PubMed ID: 2462307
[TBL] [Abstract][Full Text] [Related]
15. Safe and efficient ecotropic and amphotropic packaging lines for use in gene transfer experiments.
Markowitz DG; Goff SP; Bank A
Trans Assoc Am Physicians; 1988; 101():212-8. PubMed ID: 3077729
[TBL] [Abstract][Full Text] [Related]
16. Generation of high-titer retroviral vectors following receptor-mediated, adenovirus-augmented transfection.
von Rüden T; Stingl L; Cotten M; Wagner E; Zatloukal K
Biotechniques; 1995 Mar; 18(3):484-9. PubMed ID: 7779400
[TBL] [Abstract][Full Text] [Related]
17. Large-scale manufacturing of safe and efficient retrovirus packaging lines for use in immunotherapy protocols.
Farson D; McGuinness R; Dull T; Limoli K; Lazar R; Jalali S; Reddy S; Pennathur-Das R; Broad D; Finer M
J Gene Med; 1999; 1(3):195-209. PubMed ID: 10738568
[TBL] [Abstract][Full Text] [Related]
18. Generation of stable retrovirus packaging cell lines after transduction with herpes simplex virus hybrid amplicon vectors.
Sena-Esteves M; Hampl JA; Camp SM; Breakefield XO
J Gene Med; 2002; 4(3):229-39. PubMed ID: 12112640
[TBL] [Abstract][Full Text] [Related]
19. Construction of new retroviral producer cells from adenoviral and retroviral vectors.
Lin X
Gene Ther; 1998 Sep; 5(9):1251-8. PubMed ID: 9930327
[TBL] [Abstract][Full Text] [Related]
20. Development of a scalable process for high-yield lentiviral vector production by transient transfection of HEK293 suspension cultures.
Ansorge S; Lanthier S; Transfiguracion J; Durocher Y; Henry O; Kamen A
J Gene Med; 2009 Oct; 11(10):868-76. PubMed ID: 19618482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
